ORNIPRESSIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C45H63N13O12S2
Molecular Weight	1042.192
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)NCC(N)=O

InChI

InChIKey=MUNMIGOEDGHVLE-LGYYRGKSSA-N

InChI=1S/C45H63N13O12S2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C45H63N13O12S2
Molecular Weight	1042.192
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9587717
Curator's Comment: Description was created based on several sources, including https://gp2u.com.au/static/pdf/P/POR-8_FERRING-PI.pdf

Ornipressin (ornithine-8-vasopressin, POR-8), is a synthetic vasopressin analogue. Ornipressin produces vasoconstriction via vasopressin V1A receptor-mediated vascular smooth muscle cell contraction. Ornipressin is used to control bleeding in surgical practice. It was introduced in 1971, and approved for use in Germany, Switzerland, New Zealand and Australia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Vasopressin V1a receptor 17 Target ID: CHEMBL1889 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787	Agonist 2678	9.16 null [pEC50]
Vasopressin V1b receptor 6 Target ID: CHEMBL1921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787	Agonist 2678	8.12 null [pEC50]
Vasopressin V2 receptor 15 Target ID: CHEMBL1790 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787	Agonist 2678	9.35 null [pEC50]
Oxytocin receptor 19 Target ID: CHEMBL2049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787	Agonist 2678	7.15 null [pEC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bleeding 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9587717	Preventing		Approved 8429	POR-8 Approved Use POR-8 FERRING® (Ornipressin) is used to help control bleeding. It narrows blood vessels at the site of an operation. Indications Local administration: to induce ischaemia and haemostasis at the site of an operation in various types of surgery where bleeding is a problem. Plastic Surgery: Hair transplants, meloplasty, otoplasty, skin grafts, resection of tumours etc. Obstetrics/Gynaecology: Vaginal repair, vaginal hysterectomy, cone biopsy of cervix, episiotomy, myomectomy. ENT Surgery: Tonsillectomy, submucous resection of septum, myringoplasty etc. Other types of surgery: Neurosurgery, orofacial surgery, surgery of head and neck, abdominal and rectal surgery, care of burns (excision of eschar).

PubMed

Title	Date	PubMed
The pharmacology of ornipressin (POR-8): a local vasoconstrictor used in surgery.	1998 Mar	9587717
New, potent, selective, and short-acting peptidic V1a receptor agonists.	2011 Jul 14	21688787

Patents

Sample Use Guides

In Vivo Use Guide

POR-8 FERRING® (Ornipressin) should be diluted before use. Usually 5 I.U. (1 ampoule) is diluted in 30 mL of physiological saline. No data are available on the compatibility or stability of POR-8 FERRING® when mixed with local anaesthetic solution. The diluted solution is administered by regional infiltration at the operation site. The maximum permitted total dose for tissue infiltration is 5 I.U., due to the possibility of systemic absorption. For gynaecological surgery and laparotomies, more dilute solutions, e.g. 5 I.U. in 50 or 60 mL physiological saline are used. For ENT surgery, somewhat more concentrated solutions, 5 I.U. in 20 mL physiological saline may be required. Extemporaneous dilutions of POR-8 FERRING® should be used on the day on which they are prepared.

Route of Administration: Topical

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:39:55 GMT 2023` Edited by `admin` on `Fri Dec 15 17:39:55 GMT 2023`
Record UNII	1KTH6N080W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ORNIPRESSIN

Official Name

English

POR-8

Code

English

8-ORNITHINEVASOPRESSIN

Common Name

English

ornipressin [INN]

Common Name

English

ORNITHINE VASOPRESSIN

Common Name

English

ORNIPRESSIN [MART.]

Common Name

English

POR 8 SANDOZ

Brand Name

English

ORNIPRESSIN [MI]

Common Name

English

POR 8

Code

English

8-L-ORNITHINEVASOPRESSIN

Common Name

English

ORPRESSIN

Common Name

English

ORN(8)-VASOPRESSIN

Common Name

English

CYS-TYR-PHE-GLN-ASN-CYS-PRO-ORN-GLY-NH2 (1-6 DISULFIDE)

Common Name

English

CYS-TYR-PHE-GLN-ASN-CYS-PRO-ORN-GLY-NH2 (1-6 DISULPHIDE)

Common Name

English

Ornipressin [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

H01BA05